74606-70-5

Upstream product

• 1431723-99-7 C₁₈H₁₇NO₅ 
• 123-11-5 4-methoxy-benzaldehyde 
• 142501-48-2 (3,4,5-trimethoxyphenyl)(trimethylsilyloxy)acetonitrile 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 

Downstream Products

• 1431723-82-8 C₂₀H₂₂N₂O₄S 
• 1431723-94-2 C₁₉H₂₀N₂O₄S 
• 397334-08-6 3-(4-methoxy-benzyl)-5-(4-methoxy-phenyl)-4-(3,4,5-trimethoxy-phenyl)-3H-oxazol-2-one 

Relevant academic research and scientific papers

Design, synthesis, cytotoxic evaluation and tubulin inhibitory activity of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazole derivatives

A new series of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazoles were synthesized and their cytotoxic activities in vitro against four different cell lines (HT-29, MCF-7, NIH-3T3, AGS) were evaluated. Compound 6g bearing 3,4,5-trimethoxyphenyl moiety on ring A and 4-methoxy substituent on ring B displayed potent cytotoxic activity against all cell lines. Flow cytometry analysis and microtubule polymerization assay confirmed that cytotoxic activities of this compound were related to inhibitory effect against microtubules polymerization. Molecular modeling studies revealed that compound 6g could strongly bind to the colchicine binding site of α,β-tubulin through hydrogen bond interactions with Thrα179 and Cysβ241.

Combretoxazolones: Synthesis, cytotoxicity and antitumor activity

Two series of combretoxazolones including 3,4-diaryloxazolones (6) and 4,5-diaryloxazolones (7) were synthesized and evaluated for cytotoxicity and antitumor activity. Both series showed strong cytotoxicities against a variety of tumor cell lines. Compound 6g exhibited a significant antitumor activity in BDF1 mice bearing B16 murine melanoma cells with inhibition rates of 67 and 61% at 100 and 30 mg/kg/day, respectively.